LogoLogoMSF Science Portal
  • My saved items
logo

© Médecins Sans Frontières

MSF Science Portal
About MSF Science Portal
About MSF
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use

v2.1.4829.produseast1

Journal Article > Editorial

Urgent request for pretomanid label expansion to align with WHO guidelines and improve treatment accessibility and efficacy

Kuksa L, Andrejak C, Haecker B, Bothamley G, Calcagno A, Cirillo D, Duarte R, Fatima R, Ferlazzo G, Guglielmetti L, Günther G, Hewison C, Horsburgh C, Jäger T, Kalancha Y, Otto-Knapp R, Kranzer K, Lillebaek T, Marks G, Middelkoop K, Motta I, Rabinova V, Sommerfeld P, Tattevin P, Lange C
Download
Download
Abstract

Pretomanid is a key anti-TB drug included in the WHO list of essential medications. The current EMA-approved label for pretomanid restricts its use to the regimen comprising bedaquiline, pretomanid and linezolid (BPaL) and only for extensively drug-resistant-TB or multidrug-resistant TB, "when antibiotics used for the latter form of TB do not work or cause unacceptable side effects." This restricted use implies that the older, prolonged and poorly tolerated regimens remain the recommended treatment for most cases of drug-resistant TB. The authors, representing many respiratory groups and societies, call for the label expansion of pretomanid to align with global guidelines, allowing for broader use.


Subject Area
tuberculosisaccess to health care
DOI
10.5588/ijtldopen.25.0152
Published Date
01-Mar-2025
PubMed ID
40092518
Languages
English
Journal
IJTLD OPEN
Volume / Issue / Pages
Volume 2, Issue 3, Pages 117-119
Dimensions Badge